Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.66 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗

December 22, 2021

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Via InvestorPlace

Got $1,000? Check Out These 3 Top Biotech Stocks ↗

December 03, 2021

Two big biotechs and one smaller one that could be winners over the long term.

Via The Motley Fool

Being First Is Not Enough For Crispr Therapeutics ↗

November 15, 2021

CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.

Via InvestorPlace

In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing ↗

November 12, 2021

Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...

Via Benzinga

Cathie Wood's Buying Beam Therapeutics -- Should You? ↗

November 09, 2021

Can this high-flying gene-editing stock keep on climbing for new investors?

Via The Motley Fool

Looking Into Beam Therapeutics's Return On Capital Employed ↗

November 08, 2021

Beam Therapeutics (NASDAQ:BEAM) brought in sales totaling $763.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 18.08%, resulting in a...

Via Benzinga

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology ↗

October 19, 2021

Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗

October 19, 2021

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:

Via Benzinga

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week ↗

October 15, 2021

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Via The Motley Fool

Beam Therapeutics Stock Flashes Renewed Technical Strength ↗

October 12, 2021

On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before.

Via Investor's Business Daily

Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection ↗

September 27, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce...

Via Benzinga

Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies ↗

September 23, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) has announced new preclinical data for novel lipid nanoparticle (LNP) formulations for in vivo liver editing. ...

Via Benzinga

Beam Therapeutics's Return On Capital Employed Insights ↗

September 22, 2021

According to data from Benzinga Pro, during Q2, Beam Therapeutics's (NASDAQ:BEAM) reported sales totaled $6.00 thousand. Despite a 70.57% increase in earnings, the company...

Via Benzinga

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data ↗

September 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...

Via Benzinga

Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial ↗

September 15, 2021

The FDA has signed off Magenta Therapeutics Inc's (NASDAQ: MGTA) IND application for MGTA-117. Related Content: Magenta Therapeutics Stock Drops As FDA...

Via Benzinga

Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy? ↗

September 12, 2021

One biotech could have the inside track to profit from a major achievement in CRISPR gene editing.

Via The Motley Fool

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming ↗

September 03, 2021

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Via InvestorPlace

The 3 Best Biotech Stocks to Buy Right Now ↗

August 27, 2021

Let your portfolio reflect your personality.

Via The Motley Fool

3 Stocks to Avoid if Cathie Wood's ARK ETF Falls ↗

August 21, 2021

They likely to do the worst if Michael Burry is right.

Via The Motley Fool

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week ↗

July 16, 2021

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

Via The Motley Fool

WHO Issues Framework For Governance For Gene Editing Technologies ↗

July 12, 2021

A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or...

Via Benzinga

99 Biggest Movers From Yesterday ↗

August 06, 2021

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...

Via Benzinga

A Comprehensive Guide To Genomic ETFs ↗

July 11, 2021

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...

Via Talk Markets

Is It Too Late to Buy Intellia Therapeutics? ↗

July 10, 2021

After skyrocketing 68% last week, will this stock keep running higher?

Via The Motley Fool

Why Beam Therapeutics Climbed 64.5% in June ↗

July 08, 2021

A gene editing milestone sent the entire sector higher last month.

Via The Motley Fool

Here's What Drove Gene Editing Stocks Higher This Week ↗

July 02, 2021

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Via The Motley Fool

The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures ↗

July 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc...

Via Benzinga

61 Biggest Movers From Yesterday ↗

July 07, 2021

Gainers BSQUARE Corporation (NASDAQ: BSQR) shares climbed 77.1% to close at $7.05 on Tuesday on abnormally-high volume. The company’s stock dropped around 10% on Friday....

Via Benzinga

Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders ↗

July 01, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven...

Via Benzinga

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗

July 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

All News about Beam Therapeutics Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today